ReleaseWire

Global Cancer Immunology And Oncolytic Virology Market Report with Key Vendors, Driver, Challenges & Trends, Future Investments, Vendor Landscape Analysis & Forecast 2018 to 2023, top key players - Abbvie Inc, Adaptimmune , Aduro Biotech , Advantagene , Advaxis Immunotherapies , Amgen , Argos Therapeutics , Ariad Pharmaceuticals , Arog Pharmaceuticals , Aserta Pharmaceuticals and others

Market Research Future published a study report on Chordoma Disease Market. This report studies the global market size, industry status and forecast, disease landscape and growth. Chordoma Disease market research report categorizes the market by top pharma companies, region, type and end-use industry.

A review paper to be published in Environmental Research today concludes that the current scientific evidence supports the conclusion that mobile phone and wireless radiofrequency radiation (RFR) is cancer-causing. This paper is a review and summary of animal experimental evidence and human epidemiology studies (case-control, cohort, time trend and case studies) published after the World Health Organization's International Agency for Research on Cancer (IARC) categorized radiofrequency radiation (RFR) emissions from mobile phones and other wireless devices as a possible human carcinogen (Group 2B) in 2011. The authors conclude that the current scientific evidence strengthens and supports an upgraded classification that RFR should now be categorized as carcinogenic to humans (IARC Group 1).

September is Ovarian Cancer Awareness Month. The American Cancer Society estimates one in 78 women will be diagnosed with ovarian cancer in their lifetime. In the United States alone, there will be over 22,000 new cases of ovarian cancer diagnosed this year and over 14,000 women will die from the disease. Ovarian Cancer Awareness Month is an opportunity for organizations and people to spread awareness and education about ovarian cancer.

BriaCell Therapeutics Corp. ("BriaCell"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that the Cancer Center of Kansas (CCK) has been added as a new clinical trial site. BriaCell is currently conducting an ongoing, multicenter, Phase IIa study of Bria-IMT™ (listed in ClinicalTrials.gov as NCT03066947) in advanced breast cancer, as well as the rollover combination study of Bria-IMT™ with pembrolizumab or ipilimumab (listed in ClinicalTrials.gov as NCT03328026). Dr. Shaker R. Dakhil, Board certified in Medical Oncology and Internal Medicine, will act as the clinical site's principal investigator (PI). Under the direction of Dr. Dakhil, the Cancer Center of Kansas lists 16 offices, and 13 Sub Investigators. Dr. Dakhil will work closely with Cancer Insight, LLC., BriaCell's contract research organization, to manage the clinical and regulatory aspects of the Phase IIa clinical trial in advanced breast cancer on behalf of BriaCell.

Children and their families who are battling cancer and other debilitating diseases rely on support and assistance year round. However, their need for aid can become even more critical in the summer, when schools are closed, and busy schedules complicate transportation, meals, and other factors. American Children's Society, Inc. provides the necessary summertime assistance to these kids and their families, but they rely solely on donations from community members to accomplish this arduous task.

Matthew J. Purzycki is an inspiring American cancer survivor, who survived leukemia, 3 relapses and 2 bone marrow transplants before the age of five. He has recently decided to create a documentary film in order to inspire people with hope and positivity through his own journey of survival. Matt is now sharing his story with the world and his documentary film is titled 'Thirty Years Later', and he is raising funds and support for this project on Indiegogo's crowdfunding platform.

Dr. Sunil Pai, co-host of Take Back Your Health interviews author, survivor, and advocate, Chris Wark about his unpopular decision to decline conventional treatment after being diagnosed with cancer.

The costs associated with children's cancer and other debilitative diseases can do more than add unnecessary worry to already stressed-out parents. It can even cause families to lose access to basic utilities, or even worse, cause them to be evicted, leaving them homeless and helpless.

Donna Barats, a local Zumba instructor and 2-year ovarian cancer survivor, is offering a new, peer-led support group to make sure that other Lehigh Valley women with the disease do not have to face it alone.

BriaCell Therapeutics Corp. ("BriaCell"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it will publish its clinical findings in the American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings. ASCO's Annual Meeting, taking place June 1-5, 2018 in Chicago, IL, represents the world's largest gathering of oncology physicians, biotechnology executives, researchers, and investment analysts to discuss breakthrough clinical research and therapeutics in the field.

American Children's Society, a non-profit organization based in New Jersey, helps children with cancer and their families through car donations from Philadelphia and NJ residents. Individuals are encouraged to donate their old cars to the program, which are used to help the children receive assistance, care, and support.

BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, published a paper that sheds light on the potentially unique mechanism of action of BriaCell's lead product candidate, Bria-IMT™, in the journal of Frontiers in Immunology, the 5th most cited journal in Immunology.

Philadelphia resident Jo Holz wants to make sure that no woman with breast cancer feels alone. As a former senior market research executive at companies like NBC Universal and The Neilson Group, Holz sits on the board of SHARE, a national nonprofit offering free breast and ovarian cancer support services. This work is personal: a breast cancer survivor herself, Holz has also been a recipient of SHARE's services. Now, she is taking on a third role: Holz will be the facilitator of SHARE's first ever breast cancer support group in Philadelphia at the American Association for Cancer Research, meeting for the first time June 5.

Sally Pierre, a 30 year breast cancer survivor, wants to change the landscape of breast cancer support for Latina women in Orlando.

BriaCell Therapeutics Corp. ("BriaCell"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that it has presented two posters highlighting its most recent scientific and clinical findings of BriaCell's lead product candidate, SV-BR-1-GM, also known as Bria-IMT™, at the 2018 American Association of Cancer Research (AACR) Annual Meeting.

American Children's Society, Inc. provides opportunities to help children with cancer and their families. Monetary donations, volunteering and donating used vehicles are all excellent ways to make a difference.

BriaCell Therapeutics Corp. ("BriaCell"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Sylvester Comprehensive Cancer Center at the University of Miami is now actively screening and enrolling patients in the ongoing, multicenter, Phase IIa study of Bria-IMT™ in advanced breast cancer. Dr. Carmen Julia Calfa, a Board-Certified breast medical oncologist, will act as the clinical site's principal investigator. Dr. Calfa will work closely with Cancer Insight, LLC., BriaCell's contract research organization, to manage the clinical and regulatory aspects of the Phase IIa clinical trial in advanced breast cancer on behalf of BriaCell.

New Research on Molecular Diagnostics in Cancer Testing Market according to Type, Application Analysis, Solution, Market Outlook, Segmentation, Growth, Development and Global Forecast- Genomic Health, Genoptix, Genmark Diagnostics, Cancer Genetics, Clarient, Counsyl, Flatiron HealthNew Research on Molecular Diagnostics in Cancer Testing Market according to Type, Application Analysis, Solution, Market Outlook, Segmentation, Growth, Development and Global Forecast- Genomic Health, Genoptix, Genmark Diagnostics, Cancer Genetics, Clarient, Counsyl, Flatiron Health

BriaCell Therapeutics Corp. ("BriaCell"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the acceptance of a manuscript describing the novel mechanism of action of the Company's lead product candidate, Bria-IMT™. The findings detailed in the paper provide a rationale for the encouraging clinical results observed with Bria-IMT™ in current and past clinical testing. The publication will appear in Frontiers in Immunology, the 5th most cited journal in Immunology worldwide. Bria-IMT™, also known as SV-BR-1-GM, has caused remarkable reduction of tumor size in some patients with advanced metastatic breast cancer. Understanding Bria IMT™'s mechanism of action is extremely important, not only for developing further clinical refinements; it may shed light on basic immune mechanisms important in many other areas. BriaCell is currently enrolling patients in a Phase IIa trial (NCT03066947) with Bria-IMT™ and a rollover trial (NCT03328026) with Bria-IMT™ alone or in combination with other immunotherapies.

Scientists concluded there is "clear evidence" linking cell phone radiation to the development of cancers in rats. The U.S. government invited an expert panel to make a majority-rules declaration in response to the $25 million U.S. government National Toxicology Program (NTP) study of cell phone radiation in animals. After a three-day review of the study data, they voted to strengthen the conclusions that cell phone radiation caused health effects in the cell phone radiation exposed rats and mice. This week Scientific American and The Nation both ran stories on the topic along with The News and Observer entitling their piece, "Can your cellphone cause cancer? Scientists find definitive link in study of rats."

ProLung, Inc. ("ProLung" or the "Company") is focused on making a difference in time for lung cancer patients with its innovative predictive analytics technology and non-invasive tests for the risk stratification of indeterminate pulmonary nodules. Today ProLung announces the appointment of Mark V. Anderson, CPA as Chief Financial Officer.

For nearly the last two decades, The American Children's Society has been providing assistance to kids and their families who have been stricken with cancer and other life-threatening illnesses. While the nonprofit is perpetually dedicated to their mission and cause, for the first time in their 18-year history, they have been experiencing a considerable shortage of donations.

Researchers with the renowned Ramazzini Institute (RI) in Italy announce that a large-scale lifetime study of lab animals exposed to environmental levels of cell tower radiation developed cancer. A $25 million study of much higher levels of cell phone radiofrequency (RF) radiation, from the US National Toxicology Program (NTP), has also reported finding the same unusual cancer called Schwannoma of the heart in male rats treated at the highest dose. In addition, the RI study of cell tower radiation also found increases in malignant brain (glial) tumors in female rats and precancerous conditions including Schwann cells hyperplasia in both male and female rats.

ProLung, Inc. ("ProLung" or the "Company"), which is focused on making a difference in time for lung cancer patients with its innovative predictive analytics technology and non-invasive tests for the risk stratification of indeterminate pulmonary nodules, announces the appointment of Rex Yung, MD, FCCP as Chief Scientific Officer.